Association of sleep disorders, chronic pain, and fatigue with survival in patients with chronic kidney disease: a meta-analysis of clinical trials

被引:18
|
作者
Yang, Xiu Hong [1 ]
Zhang, Bao Long [2 ]
Gu, Yan Hong [1 ]
Zhan, Xiao Li [1 ]
Guo, Li Li [3 ]
Jin, Hui Min [1 ]
机构
[1] Fudan Univ, Shanghai Pudong Hosp, Div Nephrol, Pudong Med Ctr, 2800 Gong Wei Rd, Shanghai, Peoples R China
[2] Fudan Univ, IBS, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Hemodialysis Ctr, Bao Shan Branch, Peoples Hosp 1, Shanghai, Peoples R China
关键词
Sleep disorders; Chronic pain; Fatigue; Chronic kidney disease (CKD); Meta-analysis; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DAYTIME SLEEPINESS; DIALYSIS PATIENTS; MORTALITY; QUALITY; APNEA; SYMPTOMS; IMPACT; RISK;
D O I
10.1016/j.sleep.2018.06.020
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Sleep disorders, chronic pain, and fatigue have been long-standing torments in most patients with chronic kidney disease (CKD). In this review, we attempted to explore whether these nontraditional cardiovascular risk factors are associated with increased mortality in patients with CKD. Method: Electronic searches were performed in MEDLINE (PubMed, 1966-2018), EMBASE (1974-2018), ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials databases. All prospective or retrospective studies were considered eligible if they were cohort or observational studies and the final outcome was all-cause death or mortality. Results: We ultimately included 18 studies (12 studies on sleep disorders, three studies on chronic pain, and three studies on fatigue) in our review. Pooled analysis of all studies indicated that patients with sleep disorders, chronic pain, and fatigue had increased risks of all-cause mortality (risk ratio [RR] = 1.47, 95% confidence interval [CI] = 1.30-1.66, p < 0.0001; RR = 1.29, 95% CI = 1.27-1.31, p < 0.0001; RR = 1.45, 95% CI = 1.23-1.70, p < 0.0001, respectively). Pooled results from four studies indicated that dialysis patients with sleep-disordered breathing had increased cardiovascular disease outcomes (RR = 2.45, 95% CI = 1.74-3.44, p < 0.0001). Conclusion: Sleep disorders, chronic pain, and fatigue are remarkably associated with increased all-cause mortality in patients with CKD. Large clinical randomized controlled trials are required to further confirm the results of our meta-analysis. (c) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 50 条
  • [21] Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
    Li, Li
    Zheng, Xin
    Deng, Jin
    Zhou, Junlin
    Ou, Jihong
    Hong, Tao
    RENAL FAILURE, 2022, 44 (01) : 1112 - 1122
  • [22] CHRONIC KIDNEY DISEASE ON SURVIVAL IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS-A META-ANALYSIS
    Bissett, J. K.
    Matin, Z. M.
    Mitra, S.
    Leonardi, M.
    Sachdeva, R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (03) : 556 - 556
  • [23] Comment on association between sarcopenia and clinical outcomes in chronic kidney disease patients: A systematic review and meta-analysis
    Zhang, Xiao-Ming
    Chen, Tian-chao
    Zhang, Yi-Zhen
    He, Wan-Qiao
    Wu, Xin-Juan
    Tao, Yan-Ling
    CLINICAL NUTRITION, 2022, 41 (09) : 2047 - 2049
  • [24] Sleep disorders in pediatric chronic kidney disease patients
    Stabouli, Stella
    Papadimitriou, Eleni
    Printza, Nikoleta
    Dotis, John
    Papachristou, Fotios
    PEDIATRIC NEPHROLOGY, 2016, 31 (08) : 1221 - 1229
  • [25] Exploring sleep disorders in patients with chronic kidney disease
    Nigam, Gaurav
    Camacho, Macario
    Chang, Edward T.
    Riaz, Muhammad
    NATURE AND SCIENCE OF SLEEP, 2018, 10 : 35 - 43
  • [26] Sleep disorders in pediatric chronic kidney disease patients
    Stella Stabouli
    Eleni Papadimitriou
    Nikoleta Printza
    John Dotis
    Fotios Papachristou
    Pediatric Nephrology, 2016, 31 : 1221 - 1229
  • [27] Periodontal and chronic kidney disease association: A systematic review and meta-analysis
    Kapellas, Kostas
    Singh, Ankur
    Bertotti, Maite
    Nascimento, Gustavo G.
    Jamieson, Lisa M.
    Hughes, Jaqui
    Sajiv, Cherian
    Fernandes, David
    Pawar, Basant
    Harris, David
    Hoy, Wendy
    Cass, Alan
    Maple-Brown, Louise
    Brown, Alex
    Skilton, Micheal
    Askie, Lisa
    Bartold, P. Mark
    Arrow, Peter
    NEPHROLOGY, 2019, 24 (02) : 202 - 212
  • [28] ICDs and CRTs in patients with chronic kidney disease: a meta-analysis
    Shurrab, M.
    Zayed, Y.
    Ko, D.
    Navaneethan, S.
    Yadak, N.
    Yaseen, A.
    Qamhia, W.
    Kaoutskaia, A.
    Lee, D.
    Newman, D.
    Hamdan, Z.
    Haj-Yahia, S.
    Harvey, P.
    Crystal, E.
    EUROPEAN HEART JOURNAL, 2017, 38 : 619 - 619
  • [29] Impact of pharmacist intervention for blood pressure control in patients with chronic kidney disease: A meta-analysis of randomized clinical trials
    Nakanishi, Masanori
    Mizuno, Tomohiro
    Mizokami, Fumihiro
    Koseki, Takenao
    Takahashi, Kazuo
    Tsuboi, Naotake
    Katz, Michael
    Lee, Jeannie K.
    Yamada, Shigeki
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (01) : 114 - 120
  • [30] The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: A meta-analysis of randomized clinical trials
    Abdelazeem, Basel
    Elbadawy, Merihan A.
    Awad, Ahmed K.
    Kheiri, Babikir
    Kunadi, Arvind
    INTRACTABLE & RARE DISEASES RESEARCH, 2022, 11 (01) : 31 - 33